Abstract
In RESIST, enfuvirtide co-administered with ritonavir-boosted tipranavir was associated with higher plasma tipranavir concentrations, which seldom rose above those associated with an increased risk of grade 3/4 transaminase elevations. Transaminase elevation rates (6.5%) and clinical hepatic event rates (5.9 events/100 person exposure years) were lower in the tipranavir/ritonavir with enfuvirtide group than in the tipranavir/ritonavir without enfuvirtide group. Observed increases in plasma tipranavir concentrations thus had no apparent effect on the risk of hepatotoxicity.
Publication types
-
Research Support, Non-U.S. Gov't
MeSH terms
-
Alanine Transaminase / blood
-
Anti-HIV Agents / therapeutic use*
-
Chemical and Drug Induced Liver Injury*
-
Drug Therapy, Combination
-
Enfuvirtide
-
HIV Envelope Protein gp41 / therapeutic use*
-
HIV Fusion Inhibitors / therapeutic use
-
HIV Infections / blood
-
HIV Infections / drug therapy*
-
HIV Infections / enzymology
-
HIV Protease Inhibitors / therapeutic use
-
HIV-1*
-
Humans
-
Liver Diseases / enzymology
-
Lopinavir
-
Peptide Fragments / therapeutic use*
-
Pyridines / blood
-
Pyridines / therapeutic use*
-
Pyrimidinones / therapeutic use
-
Pyrones / blood
-
Pyrones / therapeutic use*
-
Randomized Controlled Trials as Topic
-
Ritonavir / therapeutic use
-
Saquinavir / therapeutic use
-
Sulfonamides
-
Treatment Outcome
-
Viral Load
Substances
-
Anti-HIV Agents
-
HIV Envelope Protein gp41
-
HIV Fusion Inhibitors
-
HIV Protease Inhibitors
-
Peptide Fragments
-
Pyridines
-
Pyrimidinones
-
Pyrones
-
Sulfonamides
-
Enfuvirtide
-
Lopinavir
-
Alanine Transaminase
-
Saquinavir
-
Ritonavir
-
tipranavir